PMID- 36149409
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20230129
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 112
IP  - 6
DP  - 2022 Dec
TI  - Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical 
      Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic 
      Review.
PG  - 1318-1328
LID - 10.1002/cpt.2754 [doi]
AB  - The objective of this study was to evaluate the evidence on cost-effectiveness of 
      pharmacogenetic (PGx)-guided treatment for drugs with Clinical Pharmacogenetics 
      Implementation Consortium (CPIC) guidelines. A systematic review was conducted 
      using multiple biomedical literature databases from inception to June 2021. Full 
      articles comparing PGx-guided with nonguided treatment were included for data 
      extraction. Quality of Health Economic Studies (QHES) was used to assess 
      robustness of each study (0-100). Data are reported using descriptive statistics. 
      Of 108 studies evaluating 39 drugs, 77 (71%) showed PGx testing was 
      cost-effective (CE) (N = 48) or cost-saving (CS) (N = 29); 21 (20%) were not CE; 
      10 (9%) were uncertain. Clopidogrel had the most articles (N = 23), of which 22 
      demonstrated CE or CS, followed by warfarin (N = 16), of which 7 demonstrated CE 
      or CS. Of 26 studies evaluating human leukocyte antigen (HLA) testing for 
      abacavir (N = 8), allopurinol (N = 10), or carbamazepine/phenytoin (N = 8), 15 
      demonstrated CE or CS. Nine of 11 antidepressant articles demonstrated CE or CS. 
      The median QHES score reflected high-quality studies (91; range 48-100). Most 
      studies evaluating cost-effectiveness favored PGx testing. Limited data exist on 
      cost-effectiveness of preemptive and multigene testing across disease states.
CI  - (c) 2022 The Authors. Clinical Pharmacology & Therapeutics published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Morris, Sarah A
AU  - Morris SA
AD  - Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, 
      Atrium Health, Charlotte, North Carolina, USA.
FAU - Alsaidi, Ashraf T
AU  - Alsaidi AT
AD  - Wingate University School of Pharmacy, Wingate, North Carolina, USA.
FAU - Verbyla, Allison
AU  - Verbyla A
AD  - Health Economics and Outcomes Research, Department of Biostatistics, Levine 
      Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
FAU - Cruz, Adilen
AU  - Cruz A
AD  - Health Economics and Outcomes Research, Department of Biostatistics, Levine 
      Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
FAU - Macfarlane, Casey
AU  - Macfarlane C
AD  - Wingate University School of Pharmacy, Wingate, North Carolina, USA.
FAU - Bauer, Joseph
AU  - Bauer J
AD  - Health Economics and Outcomes Research, Department of Biostatistics, Levine 
      Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
FAU - Patel, Jai N
AU  - Patel JN
AUID- ORCID: 0000-0001-9845-3697
AD  - Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, 
      Atrium Health, Charlotte, North Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20221009
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Humans
MH  - *Pharmacogenomic Testing
MH  - *Pharmacogenetics
MH  - Cost-Benefit Analysis
MH  - Warfarin/therapeutic use
MH  - Carbamazepine
PMC - PMC9828439
COIS- The authors declared no competing interests for this work.
EDAT- 2022/09/24 06:00
MHDA- 2022/11/23 06:00
PMCR- 2022/10/09
CRDT- 2022/09/23 10:54
PHST- 2022/07/20 00:00 [received]
PHST- 2022/09/17 00:00 [accepted]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/09/23 10:54 [entrez]
PHST- 2022/10/09 00:00 [pmc-release]
AID - CPT2754 [pii]
AID - 10.1002/cpt.2754 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2022 Dec;112(6):1318-1328. doi: 10.1002/cpt.2754. Epub 2022 
      Oct 9.